Overview
Tesamorelin demonstrates enhanced pharmacokinetic properties compared to endogenous GHRH, contributing to its unique therapeutic profile. The peptide is metabolized primarily through local receptor-mediated pathways and excreted through urine, with detectability up to several days post-administration using specialized assay methods.
Chemical structure & Properties
Molecular Formula: C221H366N72O67S
Molecular Weight: 5135.9 Daltons (free base)
Sequence: 44-amino acid synthetic analogue of human GHRH with trans-3-hexenoic acid modification
Half-life: 26-38 minutes (subcutaneous administration)
Stability: Enhanced resistance to dipeptidyl aminopeptidase degradation, superior to native GHRH
Regulatory Status and
Legal Considerations
FDA Status
Classification: Prescription medication for HIV-associated lipodystrophy
Approval Status: FDA-approved for specific indication (2010)
Compounding: Available through specialty pharmacies only
Regulatory Position: Approved with established safety and efficacy profile
International Status
Classification: Prohibited under S0: Non-Approved Substances
Athletic Use: Banned in competitive sports
Testing: Detectable in anti-doping screenings
Legal Availability
Commercial Status: Legally available as prescription medication
Market Presence: Distributed through specialty pharmacy networks
Quality Control: FDA-regulated manufacturing and distribution standards
Clinical Use: Approved for medical use with physician supervision
The Paragon Method: Step-by-Step
Administration Routes:
Subcutaneous injection (FDA-approved route)
Abdominal injection sites with rotation
Daily reconstitution required (Egrifta SV)
Weekly reconstitution available (Egrifta WR)
Clinical Considerations
Important Notes:
FDA-approved dosing guidelines exist for HIV indication
Individual response monitoring through IGF-1 levels
Medical supervision required for all therapeutic applications
Quality and purity guaranteed through FDA-regulated sources
Priority Research Areas
Large-scale clinical trials in non-HIV populations for metabolic disorders
Long-term cardiovascular outcome studies and safety assessment
Optimal dosing strategies for various clinical applications
Mechanism elucidation of tissue-specific growth hormone effects
Drug interaction studies with commonly prescribed medications
Emerging Applications
Research is investigating potential applications in:
Nonalcoholic fatty liver disease and hepatic steatosis
Age-related metabolic dysfunction and sarcopenia
Cognitive impairment and neuroprotective effects
General visceral adiposity in non-HIV populations
Conclusion
Tesamorelin represents a unique therapeutic peptide with established clinical benefits in HIV-associated lipodystrophy management. Its mechanism of action through physiological growth hormone stimulation offers targeted effects on visceral adipose tissue while maintaining natural hormonal feedback systems.
The extensive clinical evidence supporting tesamorelin's efficacy, combined with its FDA-approved status and established safety profile, positions it as an important therapeutic option for patients with HIV-associated lipodystrophy. The peptide's ability to reduce cardiovascular risk factors and improve body composition extends its clinical value beyond simple fat reduction.
However, applications beyond the FDA-approved indication require careful consideration and ongoing research validation. Healthcare providers considering tesamorelin therapy must evaluate individual risk-benefit profiles while ensuring appropriate medical supervision and adherence to established protocols.
Future research will be critical in expanding tesamorelin's therapeutic applications, optimizing treatment protocols, and establishing its role in broader metabolic medicine. Until comprehensive studies in general populations are completed, clinical use should focus on evidence-based indications with appropriate medical oversight and patient counseling regarding benefits and risks.
TESAMORELIN SCIENTIFIC
DATA SUMMARY
Parameter
Molecular Weight
Amino Acid Length
Half-Life
Bioavailability
Detection Window
Value
5135.9 Da (free base)
44 residues
26-38 minutes (subcutaneous)
Less than 4% (subcutaneous)
Up to 4 days (urine)
Application
Growth Hormone Release
Lipolysis Enhancement
IGF-1 Stimulation
Metabolic Function
Studies
8+ animal studies
Multiple in vitro studies
Hepatocyte studies
Rodent studies
Dose Range
0.1-0.6 mg/kg
10 ng/mL to 100 μg/mL
1-100 ng/mL
0.1-2 mg/kg
Outcome
8-hour sustained GH elevation, superior to native GHRH
Hormone-sensitive lipase activation, increased fat breakdown
Dose-dependent IGF-1 production increase
Improved glucose homeostasis, enhanced fat oxidation
Study Type
Phase III Trials
Cardiovascular Risk Study
Diabetes Safety Trial
Fat Quality Analysis
Population
806 HIV patients
Phase III subanalysis
53 type 2 diabetics
341 HIV patients
Results
19.6% and 11.7% VAT reduction (p<0.001)
0.40% reduction in 10-year ASCVD risk
No significant glucose intolerance
Improved adipose tissue density and quality
Limitations
HIV-specific population
Post-hoc analysis
Short-term study (12 weeks)
Surrogate endpoints
Parameter
Acute Toxicity
Organ Toxicity
Adverse Events
Long-term Safety
Finding
No LD50 established (up to 0.6 mg/kg tested)
No significant histologic changes in major organs
Injection site reactions (15-20%), arthralgia, myalgia
Excellent profile in extended studies
Authority
FDA
WADA
DEA
Classification
Prescription Drug
S0 Non-approved Substance
Unscheduled
Status
Approved for HIV lipodystrophy
Prohibited in sports
Not controlled substance
Peptides work best as one part of a complete, medically supervised plan. These are often used alongside our medically supervised weight loss program in Atlanta. To see how this fits your goals, explore our full approach to peptide therapy in Atlanta.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Tesamorelin is FDA-approved only for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Patients should consult with qualified healthcare providers before considering any peptide therapy.
The content reflects current scientific literature and regulatory status as of 2025.
Explore Peptide Therapy at Paragon
Peptides work best as part of a bigger plan, not on their own. At Paragon Sports Medicine in Atlanta, every peptide is prescribed by our team, guided by your labs and your goals, and matched to the right protocol for you. If you are wondering whether this one fits where you want to go, our peptide therapy program in Atlanta is the place to start.